title: Infectious complications more than 1 year after liver transplantation: a 3-decade nationwide experience.
abstract: Because few reports have addressed infections late (≥1 year) after liver transplantation (LT), we evaluated the incidence, risk factors and pathogens involved. Infection data were from the Finnish LT registry, with starting date, type and relevant pathogens for 501 Finnish adult LT patients surviving ≥1 year post-transplant. Follow-up end points were end of study, death or retransplantation. Logistic regression to assess risk factors was adjusted for age, gender and follow-up time. With 3923 person-years of follow-up, overall infection incidence was 66/1000 person-years; 155 (31%) suffered 259 infections, and two-thirds experienced only one infection. Cholangitis (20%), pneumonia (19%) and sepsis (14%) were most common. The most frequent bacteria were Enterococcus spp. and Escherichia coli, and the most frequent viruses cytomegalovirus and varicella zoster virus. Fungal infections were rare (n = 7). With 13 fatal infections, 17% of all late deaths involved infection. Primary sclerosing cholangitis (PSC) and Roux-en-Y-type biliary anastomosis were associated with cholangitis; 18% of PSC patients suffered late cholangitis. Late acute rejection was associated with sepsis. Age, gender or cytomegalovirus did not significantly influence late infections. In conclusion, although infection risk under maintenance immunosuppression therapy is relatively low, particular vigilance regarding cholangitis, pneumonia and sepsis seems appropriate.
authors.affiliation: Transplantation and Liver Surgery Clinic, Helsinki University Hospital, Helsinki, Finland. Fredrik.Aberg@helsinki.fi
authors.forename: F
authors.initials: F
authors.lastname: Aberg
authors.forename: H
authors.initials: H
authors.lastname: Mäkisalo
authors.forename: K
authors.initials: K
authors.lastname: Höckerstedt
authors.forename: H
authors.initials: H
authors.lastname: Isoniemi
mesh_terms: D000328:Adult; D001424:Bacterial Infections / Q000209:etiology; D002761:Cholangitis / Q000453:epidemiology / Q000209:etiology; D005260:Female; D005387:Finland / Q000453:epidemiology; D005500:Follow-Up Studies; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D015994:Incidence; D017053:Infection Control; D007239:Infections / Q000453:epidemiology / Q000209:etiology* / Q000401:mortality; D016031:Liver Transplantation / Q000009:adverse effects*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000209:etiology; D011014:Pneumonia / Q000453:epidemiology / Q000209:etiology; D012042:Registries; D012307:Risk Factors; D018805:Sepsis / Q000453:epidemiology / Q000209:etiology; D013997:Time Factors; D014777:Virus Diseases / Q000209:etiology